Related Experiment Video
Updated: Jul 21, 2026
07:51
The C-seal: A Biofragmentable Drain Protecting the Stapled Colorectal Anastomosis from Leakage
Published on: November 4, 2010
Permacol™ collagen paste for cryptoglandular and Crohn's anal fistula
M Brunner1, I Schneider1, K Günther2
1Department of General and Visceral Surgery, Friedrich-Alexander-University, Krankenhausstraße 12, 91054, Erlangen, Germany.
Techniques in Coloproctology
|February 14, 2019
Summary
Permacol™ paste, a collagen matrix, shows moderate effectiveness and safety for treating anal fistulae, including those in Crohn
Area of Science:
- Colorectal Surgery
- Gastroenterology
- Biomaterials
Background:
- Permacol™ paste is an acellular, crosslinked porcine dermal collagen matrix suspension.
- It represents a novel treatment option for anal fistulae, with limited existing data.
- Previous reports include only one case of Crohn's fistula treated with Permacol™ paste.
Purpose of the Study:
- To evaluate the efficacy and safety of Permacol™ collagen paste.
- To assess its use in patients diagnosed with cryptoglandular and Crohn's perianal fistulae.
Main Methods:
- Prospective study involving patients with anal fistula treated with Permacol™ paste.
- Follow-up assessments at 1 week, 6 months, 12 months, and as needed.
- Evaluation focused on fistula healing (clinical examination, proctoscopy, rectoscopy) and postoperative continence.
Main Results:
- Thirty patients (40% with Crohn's disease) were included, with an average of 6 prior fistula operations.
- Healing rates were 57% at 6 months and 63% at 12 months.
- Adverse events were minimal, including one case of worsened incontinence and two instances of perianal pain or fluid accumulation.
Conclusions:
- Permacol™ paste demonstrates moderate effectiveness in treating both cryptoglandular and Crohn's fistulae.
- The treatment is considered safe, with a low incidence of adverse events.
- Findings support Permacol™ paste as a viable option for complex anal fistula cases.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD: